Hexo received NYSE warning in early April over low stock price
Hexo is the latest Canadian cannabis producer to run afoul of the New York Stock Exchange’s continued listing standards due to a low stock price. […]
Author: The Editor
Talent database launched after Canada’s cannabis sector sheds 30% of workforce
A cannabis staffing agency in Toronto has launched a public database to connect displaced marijuana professionals with prospective employers. The initiative comes […]
Is cannabis multistate operator Harvest Health in hot water – or just busy cutting deals?
To a casual marijuana industry observer, it might seem that Arizona-based Harvest Health & Recreation has taken to heart the adage, “All […]
Cannabis lobbying group announces leadership changes
The National Cannabis Roundtable, one of the industry’s leading advocates for federal marijuana reform, appointed Cresco Labs CEO Charlie Bachtell as its […]
Work briefly halted at Ontario cannabis greenhouse over COVID-19 infection
Work was temporarily suspended at a cannabis greenhouse in Ontario owned by a one of Tilray’s subsidiaries earlier this week after a […]
Utah marijuana dispensaries prep for drive-thrus, delivery after state signoff
The coronavirus – combined with an increase in new patient demand – has convinced Utah regulators to allow the state’s medical marijuana […]
High-stakes retail wager: Q&A with marijuana publisher High Times chair, new CEO
High Times Holding Corp. Chair Adam Levin and the company’s new CEO, Peter Horvath, have an audacious plan: Take the iconic cannabis […]
Cannabis banking included in House Democrats’ $3 trillion coronavirus stimulus bill
A provision that would permit banks to serve state-legal marijuana businesses without fear of federal reprisal is part of a $3 trillion […]
Missouri lawmakers push for more medical marijuana licenses
A group of Missouri lawmakers wants to substantially increase the number of medical cannabis business permits for the market, arguing the state […]
GW Pharma trims loss to $8 million, warns virus could hit sales
GW Pharmaceuticals lost $8 million in its latest quarter – an improvement over the previous three-month period – but the United Kingdom-based medical […]